Our results revealed that approximately one-fifth of MS patients show an elevated endogenous type I IFN-like activity prior to IFN-beta treatment and that this phenomenon can be explained by a higher expression and activity of the ISGF3 complex. The gene discussed is IRF9; the disease is myeloid sarcoma.